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Summary
Foxp3+ regulatory T (Treg) cells maintain immune homeostasis by limiting different types of
inflammatory responses. Here, we report that miR-146a, one of the miRNAs prevalently expressed
in Treg cells, is critical for their suppressor function. The deficiency of miR-146a in Treg cells
resulted in a breakdown of immunological tolerance manifested in a fatal IFNγ-dependent
immune-mediated lesions in a variety of organs. This was likely due to augmented expression and
activation of signal transducer and activator transcription 1 (Stat1), a direct target of miR146a.
Likewise, heightened Stat1 activation in Treg cells subjected to a selective ablation of SOCS1, a
key negative regulator of Stat1 phosphorylation downstream of IFNγ receptor, was associated with
analogous Th1-mediated pathology. Our results suggest that specific aspects of Treg suppressor
function are controlled by a single miRNA and that an optimal range of Stat1 activation is
important for Treg-mediated control of Th1 responses and associated autoimmunity.
Introduction
A variety of pathologies are caused by the immune responses to “self” and environmental
non-microbial antigens, to microbial antigens derived from commensal microorganisms, and
to infectious agents. Regulatory T cells (Treg) limit “collateral damage” resulting from
protective immunity to infection, suppress sterile inflammation, and immune responses to
“self” and allergens (Belkaid and Tarbell, 2009; Lu and Rudensky, 2009; Sakaguchi, 2005).
Suppressive function of Treg cells is indispensable for the immune homeostasis and survival
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of higher organisms - Treg cell ablation in healthy adult mice leads to a fatal, aggressive
lympho- and myeloproliferative autoimmune syndrome (Kim et al., 2007). X chromosome-
encoded transcription factor Foxp3 plays a pivotal role in differentiation, homeostasis, and
function of Treg cells. Foxp3 loss-of-function mutations cause systemic immune-mediated
lesions similar to those observed upon chronic Treg cell ablation (Fontenot et al., 2003; Hori
et al., 2003; Khattri et al., 2003). Analyses of T cells expressing GFP-tagged null and
functional Foxp3 alleles and genome-wide analysis of Foxp3 binding genes showed that
Foxp3 directly or indirectly controls several thousand genes in Treg cells (Fontenot et al.,
2005; Gavin et al., 2007; Lin et al., 2007; Zheng et al., 2007; Lu et al., 2009; Marson et al.,
2007). These studies also revealed that a number of genes constitutively up- or down-
regulated in Treg cells in a Foxp3-dependent manner undergo corresponding changes, albeit
transient and less prominent, in activated effector T cells. This sizable cluster of “Foxp3-
amplified” genes includes those serving as hallmarks of Treg cells (CTLA4, CD25, and
GITR) and playing important functional roles in their homeostasis and function (Gavin et
al., 2007; Lin et al., 2007; Zheng et al., 2007; Marson et al., 2007). These results suggested
that Foxp3 acts in an “opportunistic” manner by amplifying and stabilizing expression of
genes beneficial to Treg cell function.
In addition to coding genes, the “Foxp3-amplified” cluster also includes several small non-
coding RNA known as microRNAs (miRNAs) (Cobb et al., 2006). Notably, miRNAs serve
as important regulators of Treg cell homeostasis and function in both basal and
inflammatory settings (Chong et al., 2008; Liston et al., 2008; Zhou et al., 2008). Ablation
of miRNA precursor-processing enzyme Dicer in Treg cells results in a reduction in their
numbers and suppressive capacity in healthy mice harboring both Dicer-deficient and -
sufficient Treg cells and a complete loss of suppressor function in diseased mice lacking
wild-type Treg cells (Liston et al., 2008). Consequently, the generalized depletion of
miRNAs in Treg cells leads to a fatal early-onset autoimmune pathology indistinguishable
from that in Foxp3 mutant mice devoid of Treg cells (Chong et al., 2008; Liston et al., 2008;
Zhou et al., 2008). These results and of the description of a subset of miRNAs differentially
expressed in regulatory vs. effector T cells (Cobb et al., 2006) raised a question as to how
individual miRNAs present in increased amounts in Treg cells contribute to distinct aspects
of their homeostasis and function. In this regard, miR-155, a well known onco-miR (cancer-
associated micro-RNA), is constitutively expressed in high amounts in Treg cells in a
Foxp3-dependent manner, whereas T cells lacking Foxp3, B cells, and myeloid cells
transiently up-regulate miR-155 upon activation (Androulidaki et al., 2009; O’Connell et al.,
2007; Thai et al., 2007). Our previous studies showed that miR-155 confers heightened
responsiveness of Treg cells to their key survival and growth factor, IL-2, thereby
maintaining their numbers in a competitive environment. However, miR-155 is largely
dispensable for Treg suppressor function (Lu et al., 2009).
Like miR-155, miR-146a is highly expressed in Treg cells and is induced upon activation of
effector T cells and myeloid cells. In the latter, miR-146a acts as a negative feedback
regulator to limit TRAF6 and IRAK1/2 mediated signaling in inflammatory settings (Hou et
al., 2009; Taganov et al., 2006), whereas in activated human T cells, miR-146a has been
suggested to oppose apoptosis and IL-2 production (Curtale et al., 2010). Thus, we explored
a role for miR-146a in Treg cells and found that this microRNA is essential for the ability of
Treg cells to restrain IFNγ-mediated pathogenic Th1 responses and associated inflammation.
In Treg cells, miR-146a-mediated down-regulation of Stat1, a key transcription factor
required for Th1 effector cell differentiation, was necessary for Treg ability to suppress Th1
responses. Furthermore, relieving negative regulation of Stat1 activation in Treg cells using
an alternative genetic approach resulted in a breakdown of immune homeostasis similar to
that observed in mice harboring miR-146a-deficient Treg cells. Thus, our results suggest
that a specific miRNA over-represented in Treg cells ensures their suppressor function by
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maintaining an optimal threshold of cytokine receptor-dependent activation of transcription
factors crucial for a particular type of immune response.
Results
Elevated miR-146a expression in Treg cells
To identify miRNAs essential for controlling Treg cell function, we examined miRNAs
differentially expressed between Foxp3+ Treg cells and Foxp3− non-Treg CD4+ T cells
(Cobb et al., 2006)(data not shown). Among miRNA overrepresented in Treg cells, miR-146
was particularly prominent. This miRNA has been implicated in negative regulation of
immune cell function, specifically in negative feedback regulation of myeloid cell activation
(Taganov et al., 2006). To study the role of miR-146 in Treg cells, we first sought to confirm
the high amounts of miR-146 in Treg cells. Since mature miR-146a and miR-146b
sequences differ by two nucleotides, it was difficult to distinguish whether miR-146a or
miR-146b or both are present in increased amounts in Treg cells. To address this issue, we
performed stem-loop based Taqman real-time RT-PCR assay, which allowed us to
distinguish miRNAs within the same family (Chen et al., 2005). As shown in Fig. S1A, the
miR-146a expression in CD4+CD25+Treg cells was sharply augmented in comparison to
that in CD4+CD25−CD62Lhi naïve T cells, while miR-146b expression was much lower.
Analysis of Treg and non-Treg cell subsets isolated from miR-146a-deficient mice
suggested that the small increase in miR-146b signal in Treg cells was likely due to
miR-146a expression since miR-146b expression could no longer be observed in miR-146a-
deficient Treg cells (Fig. S1A). In support of this notion, examination of the easily
discriminated primary miRNA transcripts demonstrated that pri-miR-146a but not pri-
miR-146b was elevated in Treg cells compared to naïve T cells(Fig. S1B). Thus, miR-146a,
but not miR-146b, was highly up-regulated in Treg cells.
miR-146a deficiency resulted in increased numbers, but impaired function of Treg cells
To assess a role for miR-146a in Treg cells, we examined Foxp3+ Treg cell subsets in the
thymus and in the peripheral lymphoid organs of miR-146a-deficient mice. These mice
develop severe lympho- and myeloproliferative syndrome at 6 months of age (M.B., K.T.
and D.B., submitted). Therefore, we analyzed miR-146a-deficient and littermate control
mice at 6-8 weeks of age prior to development of any clinical signs of autoimmune or
inflammatory disease and found comparable sizes of different thymocyte and peripheral
lymphoid and myeloid cell subsets (Fig. S1C-F and data not shown). Moreover, T cell
activation status was also similar to that observed in the wild-type (WT) littermates (Fig. S1I
and data not shown). In contrast to a reduction in Treg cell numbers observed in mice
lacking miR-155 (Lu et al., 2009), miR-146a-deficient mice contained significantly
increased numbers of Foxp3+ Treg cells in the periphery, but not in the thymus (Fig. S1G
and H). Consistent with its increased size, the miR-146a-deficient Treg cell subset exhibited
heightened proliferative activity reflected in augmented expression of Ki67 and a modest
increase in several activation markers (Fig. S1J and data not shown).
Since miR-146a is an important negative regulator of myeloid cell responses to cytokines
and TLR ligands, it was possible that increased miR146a-deficient Treg cell numbers were
due to a heightened activation status of dendritic cell (DC), but not a cell-intrinsic effect of
miR-146a deficiency. It was also possible that altered immune effector function in
Mirn146a−/− mice masked potential defects in miR-146a-deficient Treg cell-mediated
suppression. To explore these possibilities we performed a series of bone marrow (BM)
transfer studies (Fig. 1A). First, we transferred BM cells from miR-146a-deficient or -
sufficient littermates mixed with BM cells from Ly5.1+B6 mice at a 1:1 ratio into Rag2- or
TCRβδ-deficient recipients. Analysis of the resulting chimeric animals (Mirn146a−/−/B6)
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allowed us to discriminate between cell-intrinsic and cell-extrinsic effects of miR-146a
deficiency on increased Treg cell numbers. Second, by performing co-transfers of
Ly5.1+Foxp3KO BM cells in place of Ly5.1+B6 BM, we generated mice (Mirn146a−/−/
Foxp3KO) in which all Treg cells lack miR-146a because Foxp3KO precursors fail to
generate Treg cells, but all other BM derived cells originate from both miR-146a-deficient
and -sufficient BM. These mice allowed us to examine the function of miR-146a-deficient
Treg cells in a miR-146a-sufficient environment. Like chimeric mice reconstituted with
Foxp3KO BM alone, Mirn-146a−/−/Foxp3KO chimeras developed severe immune mediated
pathology including conjunctivitis, blepharitis, and dermatitis as early as 5 weeks after BM
transfer and became moribund soon thereafter (Fig. 1B). Histological examination of
Mirn146a−/−/Foxp3KO chimeras 6-7 weeks after transfer showed massive lymphocyte
activation and tissue infiltration in the lung, liver, and skin similar to that observed in mice
harboring Dicer-deficient Treg cells (Chong et al., 2008;Liston et al., 2008;Zhou et al.,
2008). In contrast, there were no clinical or histological signs of immune mediated lesions in
control Mirn146a−/−/B6 chimeras where both miR146a-deficient and -sufficient Treg cells
were present (Fig. S2).
The disease in Mirn146a−/−/Foxp3KO was not due to reduced numbers of Treg cells.
Mirn146a−/−/Foxp3KO chimeras which developed autoimmune pathology, had increased
numbers of Treg cells compared to control Mirn146a+/+/Foxp3KO animals (Fig. 1C-E).
Importantly, the difference in miR-146-deficient vs. -sufficient Treg cell numbers was also
observed in Mirn146a−/−/B6 and Mirn146a+/+/B6 mice chimeric mice where miR-146a-
deficient Treg cells compete with their wild-type counterparts (Fig. 1F and G). The observed
increase in the proportion of the miR-146a-deficient Treg cell subset in both Mirn146a−/−/
Foxp3KO and Mirn146a−/−/Ly5.1+B6 mixed chimeras suggested that miR-146a deficiency
increases Treg cell numbers in a cell-autonomous manner.
Despite their increased numbers, miR146a-deficient Treg cells were unable to restrain
activation of miR-146a-sufficient effector T cells, which was exhibited by high proliferative
activity, an increased CD62Llow cell subset, and high levels of the activation markers ICOS
and CTLA4 (Fig. 1H). In agreement with the histolopathology data and lack of clinical signs
of disease, flow cytometric analysis of control Mirn-146a−/−/Ly5.1+B6 chimeras showed
that both miR-146a-sufficient and -deficient effector T cells were kept in check by the
miR-146a-sufficient Treg cells present in these mice (Fig. 1I). These results suggested an
indispensable role of miR-146a in Treg cell-mediated immunological tolerance.
miR-146a deficiency in Treg cells resulted in dysregulated IFNγ responses
To identify the underlying mechanisms responsible for early fatal immune-mediated disease
observed in Mirn146a−/−/Foxp3KO chimeras, we first sought to examine whether miR-146a
deficiency results in a general impairment of Treg suppression function in inflammatory
settings similar to Dicer deficiency in Treg cells (Liston et al., 2008). To examine this
possibility, miR-146a-deficient Treg cells isolated from healthy Mirn146a−/−/B6 or diseased
Mirn146a−/−/Foxp3KO mice were co-cultured with miR-146a-sufficient responder CD4+ T
cells. We found that miR-146a-deficient Treg cells isolated from healthy Mirn146a−/−/B6
chimeras were as suppressive as their miR146-sufficient counterparts from control animals,
whereas miR146-deficient Treg cells from diseased Mirn146a−/−/Foxp3KO mice were more
suppressive in vitro, likely due to their activation in an inflammatory environment (Fig. 2A
and B). These results suggested that, unlike Dicer deficiency, lack of miR-146a did not
diminish the overall suppressor capacity of Treg cells reflected by an in vitro suppression
assay. Instead, a particular aspect of Treg suppressor function was likely impaired in the
absence of miR-146a.
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As mentioned earlier, miR-146a functions as a negative regulator of TLR/IL-1 signaling
pathway by targeting TRAF6 and IRAK1/2 (Taganov et al., 2006; Hou et al., 2009). A
recent study demonstrated that IL-1 stimulation results in IL-17 production in CD4+ T cells
including Foxp3+ Treg cells (Chung et al., 2009). Moreover, a critical role of IRAK1 in
promoting Th17 differentiation at the expense of TGFβ-dependent generation of peripheral
Foxp3+ Treg cells suggested a possibility that the lack of miR-146a might lead to heightened
Th17 responses, which cause the fatal autoimmunity in Mirn146a−/−/Foxp3KO chimeras
(Maitra et al., 2009). Indeed, in agreement with previous studies we found increased levels
of TRAF6 and IRAK1 in Treg and non-Treg T cells (Fig., S1K). However, we did not
observe any change in either Foxp3 induction or Th17 differentiation in vitro in the presence
or absence of miR-146a (Fig. S1L). More importantly, Th17 cell numbers were similar in
Mirn146a−/−/Foxp3KO and control Mirn146a+/+/Foxp3KO and Mirn146a−/−/B6 mice (data
not shown). Further analysis of cytokine production showed that the loss of miR-146a in
Treg cells resulted in increased production of the pro-inflammatory Th1 cytokine IFNγ by
both miR146a-deficient and -sufficient CD4 and CD8 T cells whereas production of IL-4,
IL-5, and IL-17 was unaffected (Fig. 2C; data not shown). This increase was not observed in
the presence of miR146a-sufficient Treg cells in Mirn146a−/−/B6 mice (Fig. 2F and data not
shown). The selective dysregulation of Th1 responses in the presence of miR-146a-deficient
Treg cells was in contrast to sharply increased production of multiple cytokines (IL-2, IL-4,
IL-5, IL-17, and IFNγ) in the presence of Dicer-deficient Treg cells (Liston et al., 2008).
Consistent with these findings, purified miR-146a-deficient Treg cells adoptively transferred
together with Foxp3KO CD4+ effector T cells into lymphopenic recipients failed to restrain
Th1 responses (Fig. S3).
In addition to a marked increase in IFNγ production in miR-146a-sufficient and -deficient
effector T cells, a sizable proportion of miR-146a-deficient Foxp3+ Treg cells produced
IFNγ in Mirn146a−/−/Foxp3KO mice (Fig. 2C-E). Production of IFNγ and other effector
cytokines by Treg cells is kept in check by Foxp3 likely as a “safety” feature, since Treg
cells express TCR with an increased reactivity against “self” antigens (Hsieh et al., 2006).
Loss of Foxp3 in Treg cells resulted in the acquisition of the ability to produce pro-
inflammatory cytokines, and cause tissue lesions in the absence of functional Treg cells
(Williams and Rudensky, 2007; Zhou et al., 2009). Thus, our current observations suggested
that in addition to Foxp3, miR-146a prevents acquisition of Th1-like properties by Treg
cells, i.e. restrains production of the pro-inflammatory cytokine IFNγ by Treg cells.
IFNγ blockade prevents the autoimmune disease in mice harboring miR-146a-deficient
Treg cells
Next, we examined whether the augmented IFNγ response was responsible for the
autoimmune disease observed in Mirn146a−/−/Foxp3KO chimeric mice. To address this
question, we neutralized the IFNγ activity by treating mice with IFNγ blocking antibody
starting 3 wks after BM transfer (Fig. 3A). IFNγ blockade did not affect the increases in
miR-146a-deficient Treg cell numbers (Fig. 3B), however, it rescued the disease observed in
their presence. At the time of analysis, treated Mirn146a−/−/Foxp3KO mice were disease-
free and phenotypically indistinguishable from control Mirn146a+/+/Foxp3KO mice (Fig.
3C; data not shown). In contrast, control IgG treated Mirn146a−/−/Foxp3KO mice
developed severe clinical signs of immune-mediated disease and tissue inflammation (Fig.
3C and data not shown). The effectiveness of IFNγ blockade was also manifested in
normalization of the number of T cells expressing CXCR3, a Th1-specific chemokine
receptor (Nakajima et al., 2002;Barbi et al., 2007), in IFNγ antibody-treated mice, whereas
in IgG-treated animals, CXCR3 expression on effector and Treg cells remained high (Fig.
3C and data not shown). Importantly, antibody-mediated neutralization of IFNγ and rescue
of Th1-mediated disease in Mirn146a−/−/Foxp3KO mice were not associated with
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measurable increases in IL-4 or IL-17 (Fig. 3D). These results suggested that miR-146a-
deficient Treg cells were able to restrain Th2 and Th17, but not Th1 responses and that
immune-mediated lesions observed in the presence of miR-146a-deficient Treg cells were
IFNγ dependent. Since an increase in numbers of miR-146a-deficient Treg cells was
unaffected by IFNγ neutralization, these experiments also imply that Treg cell homeostasis
and suppressor function are likely controlled by miR-146a via distinct molecular
mechanisms.
miR-146a regulates Stat1 in Treg cells
Next, we sought to explore molecular mechanisms underlying miR-146a-dependent Treg
cell-mediated Th1 regulation. In addition to the aforementioned miR-146a targets, TRAF6
and IRAK1, a recent study has suggested that Stat1 is a miR-146a target in human PBMCs
(Tang et al., 2009). Since Stat1 is a key transcription factor downstream of IFNγ receptor
signaling, it was possible that Stat1 expression in miR-146a-deficient Treg cells was
increased and could account for the IFNγ-/Th1-dependent immune mediated lesions
observed in Mirn146a−/−/Foxp3KO chimeras. However, unlike the 3′ UTR of the human
Stat1 gene, which contains a perfect match with the miR-146a seed sequence, no canonical
target sequence was found in the mouse Stat1 gene. Nevertheless, a highly conserved
sequence with partial complementary to miR-146a was present in the mouse Stat1 3′UTR
(Fig. 4A). Although computational algorithms relying on miRNA seed sequence analysis
failed to identify mouse Stat1 as a miR-146a putative target, it was recently shown that some
microRNAs, like miR-24, control multiple genes in the absence of canonical target seed
sequences (Lal et al., 2009). Thus, it was possible that miR-146a might recognize mouse
Stat1 through “seedless” yet conserved complementary sequences. Indeed, transfection of
mouse Stat1 3′ UTR-containing luciferase reporter into miR-146a-sufficient, but not
miR-146a-deficient T cells showed repression of reporter activity, which was abolished
upon mutagenesis of the putative miR-146a binding site (Fig. 4B). Moreover, miR-146a
overexpression in HEK293 cells reduced luciferase reporter activity (data not shown).
Finally, we found ~3-4-fold increase in total Stat1 protein in both Treg and non-Treg cells
lacking miR-146a. Together, these results suggested mouse Stat1 serves as a target of
miR-146a in mouse T cells (Fig. 4C). Levels of phosphorylated Stat1 were also markedly
increased in miR-146a-deficient cells. Consistent with the rescue from disease, Stat1
phosphorylation returned to basal level in chimeric mice treated with IFNγ antibody,
whereas the total Stat1 amounts were only partially diminished (Fig. 4C). Elevated levels of
TRAF6 and IRAK1 in miR-146a-deficient T cells were largely unaffected by IFNγ antibody
treatment and, thus, demonstrate the specificity of the observed effects of IFNγ
neutralization.
miR-146a controls Treg cell-mediated regulation of IFNγ response through targeting Stat1
To test the hypothesis that increased Stat1 expression in the absence of miR-146a is
responsible for the observed failure of Treg cells to control Th1 response, we conducted a
“loss-of-function” experiment by generating miR-146a-deficient mice harboring a single
functional Stat1 allele (Mirn146a−/− Stat1+/−=). We co-transferred Mirn146a−/− Stat1+/−
and Ly5.1+Foxp3KO bone marrow cells mixed at 1:1 ratio into Rag2-d or TCRβδ-deficient
recipients (Mirn146a−/−Stat1+/−/Foxp3KO). As shown in figure 4D, both Treg cells and
non-Treg T cells isolated from Mirn146a−/−Stat1+/−/Foxp3KO mice exhibited ~50%
reduction in total and phosphorylated Stat1 amounts compared to corresponding
Mirn146a−/−Stat1+/+/Foxp3KO controls. As a result, Mirn146a−/−Stat1+/−/Foxp3KO mice
developed a much milder and delayed immune-mediated pathology (Fig. 4E and data not
shown). In agreement with a milder disease phenotype, we observed significantly reduced
IFNγ secretion by both miR-146a-sufficient and -deficient effector CD4+ T cells.
Furthermore, reduced Stat1 expression markedly diminished IFNγ production by miR-146a-
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deficient Treg cells (Fig. 4F). Interestingly, reduced IFNγ production was accompanied by a
substantial increase in IL-4 producing miR-146a-sufficient and –deficient effector CD4+ T
cells in Mirn146a−/−Stat1+/−/Foxp3KO chimeric mice (Fig. 4G). Together, these results
provided genetic evidence that miR-146a ensures Treg cell-mediated control of Th1
responses at least in part through targeting Stat1 and that limiting Stat1 expression in
miR-146a-deficient Treg cells moderates these responses.
IFNγ production by miR-146a-deficient T cells contributes to, but does not fully account
for pathogenic Th1 responses in Mirn146a−/−/Foxp3KO mice
The mixed bone marrow transfers using miR-146a-deficient hematopoietic stem cells
revealed an important role for miR-146a in Treg cells and suggested that miR-146a
deficiency in these cells leads to Th1 mediated disease. However, we cannot formally
exclude potential contribution to the disease by other miR-146a-deficient cell subsets in
addition to Treg cells. In addition, the generation of miR-146a-deficient “former” Treg cells
due to the loss of Foxp3 by some Treg cells upon adoptive transfer into lymphopenic hosts
raises a question as to whether miR-146a deficiency in Treg cells could solely account for
dysregulation of Th1 responses (Fig. S3A). Since miR-146a deficiency resulted in a similar
level of Stat1 up-regulation and activation in both Treg and effector T cells (Fig. 4C and D),
it is plausible that IFNγ production resulting from unrestrained Stat1 activation in
miR-146a-deficient T effector cells contributed to the disease in chimeric mice harboring
miR-146a-deficient Treg cells. Consistent with this possibility, we found that miR-146a-
deficient T cells exhibited elevated IFNγ, but not IL-4 production upon activation under
non-polarizing Th0 condition (Fig.5A).
To dissociate a role of miR-146a in Treg cell-mediated suppression from its role in
restraining IFN-γ production by T effector cells, we generated miR-146a-deficient mice
lacking IFNγ (Mirn146a−/− Ifng−/−). We transferred Mirn146a−/− Ifng−/− and
Ly5.1+Foxp3KO BM cells mixed at 1:1 ratio into Rag2- or TCRβδ-deficient recipients (Fig.
5B). These Mirn146a−/−Ifng−/−/Foxp3KO mice allowed us to assess a role of miR-146a in
Treg cell-mediated suppression of pathogenic Th1 responses without a confounding effect of
the IFNγ production by miR-146a-deficient cells. We found that even in the absence of IFNγ
supplied by miR-146a-deficient cells, Mirn146a−/−Ifng−/−/Foxp3KO developed
autoimmune disease accompanied by markedly augmented IFNγ production by miR-146a-
sufficient CD4+ and CD8+ T cells (Fig. 5C and D). Consistent with the increased IFNγ
production, miR-146a-sufficient effector CD4+ T cells displayed an activated phenotype
along with elevated CXCR3 expression (Fig. 5E). These results provide further support for
the notion that miR-146a plays an indispensable role in Treg cell-mediated Th1 regulation.
Nevertheless, it must be noted that miR-146a-sufficient T cells from Mirn146a−/−Ifng−/−/
Foxp3KO mice produced less IFNγ and were less activated in comparison to those from
Mirn146a−/−Ifng+/+/Foxp3KO mice. This observation suggested that IFNγ production by
miR-146a-deficient cells contributed to, but does not fully account for the development of
severe Th1 pathology in the presence of miR-146a-deficient Treg cells (Fig. 5C and D).
Thus, miR-146a limits Th1 responses in two ways: by endowing Treg cells with the ability
to suppress Th1 responses and by negatively regulating T effector cells in a cell-autonomous
manner. Corresponding to this role in the Th1 response, we found higher levels of miR-146a
in both T effector and Treg cells with Th1-like features (CXCR3+T-bethi) in comparison to
their CXCR3−T-betlow counterparts (Fig.5F-I).
Unrestrained Stat1 activation in Treg cells results in IFNγ-mediated Th1 pathology
Considering that each miRNA regulates multiple targets, it was important to examine the
consequences of altering Stat1 activation in Treg cells by means other than the manipulation
of miR146a expression. Therefore, we performed a “gain-of-function” experiment by
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analyzing mice with a Treg-specific ablation of SOCS1, a negative regulator of Stat1.
Although SOCS1 also controls other signaling pathways, loss of SOCS1-dependent negative
regulation of Stat1 is the major contributor to the IFNγ-mediated immunopathology in mice
with SOCS1 deficiency (Kubo et al., 2003; Alexander et al., 1999; Horino et al., 2008;
Marine et al., 1999). As shown in Fig. 6A-F, increased Treg cell numbers were observed in
Foxp3CreSocs1fl/fl mice. This is likely due to augmented IL-2R/Stat5 signaling (Fig. S4)(Lu
et al., 2009; Zhan et al., 2009). However, despite this increase in Treg number,
Foxp3CreSocs1fl/fl mice showed clinical signs of immune-mediated pathology including
conjunctivitis, blepharitis, and dermatitis by 6 weeks of age (Fig. 6G). Furthermore, both
SOCS1-sufficient effector T cells and SOCS1-deficient Treg cells in Foxp3creSOCS1fl/fl
mice exhibited an activated phenotype (Fig. 6H, I and data not shown).
Next, we sought to examine effector mechanisms that account for the disease observed in
Foxp3creSOCS1fl/fl mice. Like miR-146a-deficient Treg cells, SOCS1-deficient Treg cells
had unimpaired in vitro suppression activity (Fig. 7A). As expected SOCS1 deficiency in
Treg cells resulted in unrestrained Stat1 activation in Treg cells (Fig. 7B). And similar to our
observations in Mirn146a−/−/FoxP3KO chimeras, these mice exhibited selective
dysregulated IFNγ production by both Foxp3+ and Foxp3− CD4+ T cell as well as CD8+ T
cells. (Fig. 7C and D). Although both Mirn146a−/−/Foxp3KO chimeras and
Foxp3creSOCS1fl/fl mice exhibited Th1-related pathology, clinical disease manifestations
were significantly less severe in the latter mice. A likely explanation for the observed
difference was that generation of BM chimeras required irradiation and was accompanied by
transient lymphopenia. Indeed, we found that Foxp3creSOCS1fl/fl /Foxp3KO chimeras
generated upon transfer of Foxp3KO and Foxp3creSOCS1fl/fl BM at 1:1 ratio into Rag2- or
TCRβδ-deficient recipients (Fig. S5A) exhibited an accelerated kinetics and increased
severity of autoimmune disease in a close resemblance to Mirn146a−/−/Foxp3KO mice (Fig.
S5B-D).
Together, our studies suggest that elevated miR-146a expression in Treg cells is required for
control of IFNγ-mediated Th1 immune responses at least in part through targeting Stat1, a
key molecule in the IFNγ signaling pathway. Our results further imply that excessive
effector cytokine signaling in Treg cells may lead to their failure to suppress the
corresponding response and consequently brings about severe autoimmunity.
Discussion
Diverse molecular mechanisms control the function of Foxp3+ Treg cells, which serve as
critical guardians of immune homeostasis. Very recently, miRNA-mediated post-
transcriptional regulation of gene expression in Treg cells has attracted considerable
attention because of the devastating failure of immunological tolerance observed in mice
with Treg cell-specific ablation of Dicer and Drosha-dependent miRNAs (Chong et al.,
2008; Liston et al., 2008; Zhou et al., 2008). These mice, like Foxp3null mice, which are
genetically devoid of Treg cells, develop unprovoked Th1, Th2, and Th17 responses and die
before 4 weeks of age from severe immune-mediated lesions in a variety of organs (Chong
et al., 2008; Liston et al., 2008; Zhou et al., 2008). In an effort to identify specific miRNAs
contributing to Treg function, we discovered that miR-155, whose elevated expression in
Treg cells is driven by Foxp3, confers competitive fitness to Treg cells by increasing
sensitivity of IL-2R signaling through targeting SOCS1. However, miR-155 was dispensable
for suppressor function of Treg cells despite its non-redundant role in Treg homeostasis
(Kohlhaas et al., 2009; Lu et al., 2009). Another recent study suggested that high level of
cAMP expression in Treg cells is conditional upon low amounts of miR-142-3p and that
forced expression of this miRNA in Treg cells attenuates their ability to suppress T cell
proliferation in vitro (Huang et al., 2009). However, the striking loss of suppressor function
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observed in Dicer-deficient Treg cells is most likely due to loss of miRNAs that are
overrepresented in these cells (Liston et al., 2008). Here, we demonstrate an essential role
for one miRNA, miR-146a, in Treg cell function in vivo by analyzing chimeric mice
generated upon co-transfer of miR-146a-deficient and Foxp3-deficient or wild-type B6 bone
marrow cells into lymphopenic recipients. The presence or absence of miR-146a-sufficient
Treg cells represented the sole difference between the resulting Mirn146a−/−/Ly5.1+B6 and
Mirn146a−/−/Foxp3KO mixed chimeras. Chimeric mice harboring only miR-146a-deficient
Treg cells, but not mice harboring both miR-146a-deficient and -sufficient Treg cells,
succumbed to severe autoimmune disease early after bone marrow reconstitution
demonstrating an indispensable role of miR-146a in Treg cell-mediated suppression.
Foxp3-dependent suppressor program implemented by Treg cells keeps in check different
types of effector immune responses to “self” antigens and pathogens. Several recent studies
revealed that Treg cells do not seem to execute a universal hard-wired functional program
limiting all kind of inflammation and immunity but instead these cells exhibit distinct
mechanistic requirements for suppression of particular classes of the immune response. For
example, Irf4, a transcription factor required for Th2 differentiation, is expressed in Treg
cells in a Foxp3 dependent manner and endows them with the ability to suppress Th2
responses (Zheng et al., 2009). Similarly, the expression of T-bet, another key transcription
factor in Th1 effector cell differentiation, is induced in Treg cells in a Stat1-dependent
manner in response to IFNγ signalling and enables them to proliferate, migrate to, and
accumulate at the sites of Th1 responses (Koch et al., 2009). Likewise, we have found that
Treg cell-restricted ablation of Stat3, a transcription factor required for Th17 induction,
leads to uncontrolled Th17 dependent pathology (Chaudhry et al., 2009). These studies
suggest that in Treg cells distinct suppressor mechanisms are tailored to fit particular tissue
and inflammatory settings by the same transcription factors which guide effector T cell
differentiation in response to similar cues. In this study, we extended this concept to
miRNAs by demonstrating that fatal immune mediated lesions observed in the presence of
miR-146a-deficient Treg cells were accompanied by sharply augmented Th1 responses and
were dependent upon increased amounts of IFNγ.
Activation of the transcription factor Stat1 downstream of the IFNγ receptor facilitates
differentiation of Th1 cells and forced expression of a Stat1-encoding transgene in T cells
results in an IFNγ-mediated immunopathology (Siebler et al., 2003). A connection between
miR-146a and Stat1, a key transcription factor in IFNγ response, was suggested by two
recent studies implying that Stat1 serves as a miR-146a target in human lymphocytes and
monocytes (Cameron et al., 2008; Tang et al., 2009). Despite the lack of a canonical
miR-146a site in the 3′UTR of the mouse Stat1 gene, it contains a highly conserved site with
partial complementarity to miR-146a seed sequence and additional complementarity in the
adjacent sequence. Luciferase reporter assays demonstrated that this putative miR-146a
binding site is crucial for miR-146a-mediated repression of Stat1. In addition, we have
currently employed the HITS-CLIP (high-throughput sequencing of RNA isolated by
crosslinking immunoprecipitation) approach to identify miR targets in T cells. Our
preliminary data confirmed the proposed region for miR-146a binding in the mouse Stat1
gene (data not shown). More importantly, the disease observed in mice harboring miR-146a-
deficient Treg cells was largely alleviated when miR-146a deficiency was coupled with
Stat1 hemizygosity. Finally, important independent confirmation of this biological
significance of restraining Stat1 activation in Treg cells for their ability to suppress Th1
responses was provided by our finding in Foxp3creSOCS1fl/fl mice and Foxp3creSOCS1fl/fl /
Foxp3KO chimeras. These mice, which harbor SOCS1-deficient Treg cells, develop IFNγ-
mediated Th1 immunopathology similar to that observed in the presence of miR-146a-
deficient Treg cells. Together, these findings offer genetic support for the notion that
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miR-146a ensures Treg cell-mediated regulation of Th1 responses, in a significant part,
through targeting Stat1.
Importantly, analysis of Mirn146a−/−Ifng−/−/Foxp3KO and Mirn146a−/−/Foxp3KO
chimeric mice revealed that miR-146a-deficient Treg cells were unable to prevent
pathogenic Th1 responses and associated disease regardless in the absence of IFNγ supplied
by the miR-146a-deficient compartment. Nevertheless, these experiments also showed that
IFNγ production by miR-146a-deficient T effector cells contributed to full-scale Th1
immunopathology in Mirn146a−/−/Foxp3KO mice. It is noteworthy that miR-146a was the
first identified miRNA with an increased expression in terminally differentiated Th1 cells
(Monticelli et al., 2005). Thus, miR-146a-mediated Stat1 repression in activated T effector
cells likely serves as a mechanism of negative feedback regulation of Th1 responses.
Moreover, our observation of higher levels of miR-146a in both Treg and effector T cells
with “Th1 like” features (CXCR3+T-bethi) in comparison to their CXCR3−T-betlow
counterparts suggested that Treg cells further increase miR-146a expression in Th1
environment to ensure effective suppression of Th1 responses. Consistent with this model,
the presence of miR-146a-sufficient Treg cells in Mirn146a−/−/Ly5.1+ B6 chimeric mice
was able to keep in check of Th1-prone effector T cells derived from miR-146a-deficient
compartment. Together, our data demonstrated an important role of miR-146a in both Treg
cell-mediated Th1 regulation and in limiting Th1 responses in a T effector cell-intrinsic
manner.
In addition to Stat1, miR-146a was previously shown to negatively regulate TLR/IL-1R
signaling pathway in macrophages by targeting TRAF6 and IRAK1/2 (Hou et al., 2009;
Taganov et al., 2006). Indeed, levels TRAF6 and IRAK1 proteins were increased in both
miR-146a-deficient Treg and non-Treg T cells. It has been shown that IL-1R signaling
facilitates Th17 differentiation and IL-17 production (Chung et al., 2009; Maitra et al.,
2009). Furthermore, Th2 responses are also facilitated by signaling through IL-1R and
IL-33R, another TRAF6/IRAK-dependent IL-1R family member (Ben-Sasson et al., 2009;
Schmitz et al., 2005). Thus, according to the idea of “symmetry” between cues eliciting
effector T cell differentiation and corresponding suppressor capability in Treg cells,
miR-146a deficiency in Treg cells could also result in augmented Th17 or Th2 responses.
However, the lack of Th2 or Th17 cytokine production in mice harboring miR-146a-
deficient Treg cells and the unimpeded ability of miR-146a-deficient Treg cells to suppress
in vitro proliferative responses of T cells demonstrated that miR-146a deficiency in Treg
cells results in a selective impairment in their ability to regulate Th1 responses. Lack of a
detectable increase in Th2 and Th17 responses in the presence of miR-146a-deficient Treg
cells can be explained by the fact that IFNγ/Stat1 signaling, while promoting Th1 immune
response, inhibits the differentiation and function of Th2 and Th17 cells (Hu and Ivashkiv,
2009). Thus, it is possible that the potential impact of dysregulated TRAF6/IRAK1 signaling
in miR-146a-deficient Treg cells was masked by the dominant effect of elevated Stat1
expression and activation. In support of this idea, combined miR-146a deficiency with Stat1
hemizygosity in Treg cells resulted in an increase in IL-4 producing Th2 cells in addition to
the aforementioned decrease in IFNγ-producing Th1 cells.
Although the heightened Stat1 activation associated with miR-146a and SOCS1 deficiency
in Treg cells impaired their ability to suppress Th1 responses, the numbers of miR-146a- and
SOCS1-deficient Treg cells were markedly increased compared to their wild-type
counterparts. Whereas an increase in size of SOCS1-deficient Treg subset is most likely a
consequence of augmented IL-2R signaling and Stat5 phosphorylation (Lu et al., 2009),
miR-146a deficiency did not alter Stat5 expression or activation (data not shown). In
addition, miR-146a-deficient Treg cell number was not decreased by the attenuated Stat1
phosphorylation and inflammation that accompanied antibody-mediated blockade of IFNγ
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signaling in chimeric mice, or Stat1 haploinsufficiency. These findings suggested that de-
repression of miR-146a targets other than Stat1 likely contributed to the increased Treg cell
numbers in miR-146a-deficient mice.
Our findings that miR-146a- or SOCS1-deficient Treg cells fail to control Th1 responses
likely due to unrestrained expression and activation of Stat1 may appear to fit the
aforementioned concept of “symmetry” in the integration of environmental cues by Treg and
effector T cells. However, whereas in previous studies it was the lack of Th lineage specific
transcription factors Stat3, Irf4, and T-bet in Treg cells that resulted in impaired suppression
of Th17, Th2, and Th1 responses, respectively; in this study unrestrained activation of Stat1
led to immunopathology. Importantly, Stat1 as well as IFNγ receptor (IFNγR) expression in
Treg cells are necessary for T-bet induction in Treg cells, a prerequisite for efficient
suppression of Th1 responses (Koch et al., 2009). The observations that both the lack of
Stat1 and unrestrained Stat1 activation resulted in a breakdown of immunologic tolerance
suggested that Treg-mediated suppression of Th1 mediated immunopathology is dependent
upon a certain optimal range of Stat1 activation by cytokines. Moreover, by limiting Stat1
amounts in Treg cells, miR-146a prevents their deviation into IFNγ-producing “Th1-like”
cells and thereby, safeguards their function and identity in inflammatory settings.
Our findings also raise a question as to why miR-146a- or SOCS1-deficient Treg cells fail to
control Th1 responses. Chemokine receptor CXCR3, a well characterized target of T-bet
(Beima et al., 2006; Lord et al., 2005), is induced in Treg cells in a T-bet-dependent manner
and endows them with the ability to migrate to the sites of Th1 responses, a prerequisite for
their efficient regulation (Koch et al., 2009). However, CXCR3 expression on the surface of
Treg cells was elevated in the absence of miR-146a or SOCS1 consistent with increased
Stat1 activation. This finding leads to the next fundamental question as to how do
miR-146a- or SOCS1-deficient Treg cells lose control of Th1 responses. It is possible that
IFNγ secreted by Treg cells could facilitate pathogenic Th1 responses since a sizable
fraction of both miR-146a- and SOCS1-deficient Treg cells produce IFNγ. In addition, our
previous microarray and phenotypic analyses have shown that IFNγR is upregulated in
Foxp3+Treg cells vs. naïve T cells in a Foxp3-dependent manner. Furthermore, a recent
study by the Belkaid group has demonstrated that during lethal T. gondii infection exposure
of wild-type Treg cells to high amounts of Th1 inflammatory mediators superimposes Th1
effector program on Treg cells. Consequently, Treg cells produce IFNγ and potentially
contribute to the tissue damage leading to death of the infected host (Oldenhove et al.,
2009). Together, these findings raise a possibility that an autocrine loop amplifies Stat1
activation and IFNγ production in miR-146a- and SOCS1-deficient Treg cells, and that overt
IFNγ signaling in miR-146a-deficient and SOCS1-deficient Treg cells results in the
breakdown of a yet unidentified mechanism of Treg cell-mediated suppression of Th1
responses. In supporting this notion, reduced pathogenic Th1 responses were observed in
chimeric mice harboring miR-146a-deficient Treg cells incapable of secreting IFNγ.
Nevertheless, lack of IFNγ production by miR-146a-deficient non-Treg cells precludes clear
conclusions drawn from these studies. Further genetic studies employing Treg cell-specific
ablation of IFNγ and IFNγR are required to directly test this idea.
In summary, our studies demonstrated that a single miRNA, miR-146a, is indispensable for
suppression mediated by Treg cells in vivo. Excessive activation of Stat1 in Treg cells is
kept in check by miR-146a to ensure efficient control of spontaneous IFNγ-dependent Th1-
mediated immunopathology and prevent deviation of activated Treg cells into IFNγ-
producing Th1-like cells. Similar lesions observed in mice with Treg cell-specific ablation
of SOCS1 lend further support to this notion. Our observations combined with the
previously reported requirement for Stat1-dependent T-bet induction in Treg cells (Koch et
al., 2009) suggest that a certain optimal range of Stat1 activation maintained by miR-146a is
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important for Treg-mediated control of Th1 responses and that both lack of Stat1 and
unrestrained Stat1 activation in Treg cells lead to a severe failure of immunologic tolerance.
Experimental procedures
Mice
Mirn146a−/− (Boldin et al., submitted), Foxp3KO (Fontenot et al., 2003), Foxp3YFP-cre
(Rubtsov et al., 2008), SOCS1fl (Tanaka et al., 2008), and Stat1−/− (Meraz et al., 1996) mice
were housed under SPF conditions. Disease development was monitored by frequent visual
examination and histopathological analyses. All mice were used in accordance with
guidelines from the Institutional Animal Care Committee of the Memorial Sloan-Kettering
Cancer Center.
Quantitative PCR analysis
Total RNA (including microRNA) was prepared from FACS purified cells using miRNeasy
kit (Qiagen). For detecting the miR-146a and miR-146b expression levels, Taqman “stem-
loop” real-time RT-PCR was performed as demonstrated previously (Jazdzewski et al.,
2008). For measuring primary miR-146a and miR-146b, first strand complementary DNA
was synthesized by using iScript cDNA synthesis kit (Bio-Rad) followed by real-time PCR
analysis (SYBR green; Applied Biosystems).
Generation of bone-marrow chimeras mice and in vivo IFNγ neutralization
Mixed bone marrow chimeras were generated as described elsewhere (Lu et al., 2009).
Briefly, T cell-depleted bone marrow cells from mice of indicated genotypes were mixed at
1:1 ratio and injected into T cell-deficient Rag2−/− or in some cases Tcrβ/Tcrδ−/− irradiated
(950 rads) hosts (3-5×106 total cells/recipient). Clinical signs, tissue histology as well as the
immune cell subset composition in the thymus and secondary lymphoid tissues were
examined 6 weeks after BM transfer or when mice became moribund. In some experiments,
mixed BM chimeras were administrated i.p. with 0.5 mg neutralizing IFNγ antibody (clone
XMG1.2) or isotype-matched control IgG weekly starting at 3 wks after BM transfer.
In vitro suppression assay
The ability of miR146-deficient and –sufficient Treg cells to suppress proliferative
responses of T cells was assessed in a standard in vitro suppression assay (Liston et al.,
2008). Briefly, FACS purified 4×104 naive Ly5.1− CD4+CD25−CD62Lhi T cells and
Mirn146a+/+ or Mirn146−/− Ly5.1−CD4+CD25hi Treg cells isolated from the mixed BM
chimeras were mixed at the indicated ratios and stimulated with CD3 antibody in the
presence of irradiated (2000 rads) splenocytes . T cell proliferation was assessed by with 3H-
TdR incorporation (cpm) in triplicate cultures during the last 8 hr of culture.
Flow cytometry and cytokine secretion assays
Cell surface staining and flow cytometric analysis of CD4, CD8, CD25, CD62L, CD103,
GITR, ICOS and CXCR3 (all eBioscience) expression were performed as described
elsewhere (Fontenot et al., 2005). Intracellular staining of Foxp3, IL-4, IFNγ, CTLA-4 (all
eBioscience) and Ki67 (BD bioscience) were performed following fixation and
permeabilisation according to manufacturer′s instructions.
To measure T cell cytokine production, 2×106 splenocytes were stimulated in 24-well plates
with PMA (50 ng/ml) and ionomycin (250 ng/ml) in the presence of “Golgi plug” (BD
Biosciences) for 5 hrs at 37 °C before staining.
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Luciferase reporter assay
CD4+ T cells isolated from Mirn146a−/− or Mirn146a+/+ mice were cultured in 12-well
plates (1×106 cells/well) and transfected with psiCheck2 luciferase reporter plasmids
(Promega) containing either wild-type or mutated Stat1 3′ UTR using Amaxa mouse T cell
nucleofector kit (Lonza, Basel, Switerland). Cells were harvested 24 hr later and luciferase
activity was assessed using Dual-Luciferase Reporter Assay System (Promega) according to
manufacturer′s protocol.
Western blot analysis
Cell lysates from miR146a-sufficient or -deficient Ly5.1−CD4+CD25−CD62Lhi T cells and
Ly5.1−CD4+CD25hi Treg cells FACS purified from the mixed BM chimeras were separated
by SDS-PAGE (5×105/lane) subjected to Western blot analysis as described previously (Lu
et al., 2009). In some experiments, CD4+Foxp3− T cells or CD4+Foxp3+ T cells isolated
from Foxp3creSOCS1fl/fl mice or control littermates were used. Antibodies against TRAF6
(04-451; Miliipore), IRAK1 (NBP1-03169; Novus), Stat1 (9172), phospho-Stat1 (9167),
Stat5 (9363), phospho-Stat5 (#9359; all from Cell Signaling Technology) and β-actin
(AC-74, Sigma) were used to visualize the corresponding proteins. Protein quantitation was
performed using NIH Image J software (http://rsb.info.nih.gov/ij/).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig 1. miR-146a-deficient Treg cells failed to effectively control immune homeostasis and
restrain miR-146a-sufficient effector T cells
(A) Schematic of generation of mixed BM chimeras. (B) Kaplan-Meyer survival plot of
mixed BM chimeras generated upon reconstitution of irradiated Rag2−/− (or TCRβδ−/−)
recipients with 1:1 mixtures of indicated BM cells. 40% of mice in Mirn146a−/−/Foxp3KO
group died before the day of analysis (arrow). The rest of the mice in this group along with
other control groups were euthanized and analyzed. Splenic Treg cell frequencies in
Mirn146a−/−/Foxp3KO and Mirn146a−/−/B6 chimeric mice generated upon transfer of
Mirn146a−/− BM mixed with Ly5.1+ Foxp3KO BM (C) or Ly5.1+ B6 BM (D) 6-7 weeks
after BM transfer. The proportion (E) and absolute numbers (F) of Ly5.1-Foxp3+ Treg cells
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in indicated chimeric mice. (G) The ratios of Ly5.1−Foxp3+ and Ly5.1+Foxp3+ cells in
indicated chimeric mice are shown. Expression of activation markers and Ki67 in miR-146a-
sufficient Ly5.1+Foxp3− Teff cell subsets from mirn146a−/−/Foxp3KO and mirn146a+//
Foxp3KO (H) or mirn146a−/−/B6 and mirn146a+/+/B6 BM (I) 6-7 weeks after BM transfer.
Data are representative of three independent experiments (n=11-13); values represent the
mean +/− s.d., *P<0.05. See also Figure S1 and S2.
Lu et al. Page 18
Cell. Author manuscript; available in PMC 2011 March 17.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig 2. Selective dysregulation of IFNγ responses in mice harboring miR-146a-deficient Treg cells
miR-146a-deficient or -sufficient Treg cells isolated from (A) healthy Mirn146a−/−/B6 or
(B) diseased Mirn146a−/−/Foxp3KO chimeric mice were co-cultured with wild-type
responder CD4+ T cells at the indicated ratios for 72h in the presence of CD3 antibody and
irradiated T cell-depleted splenocytes. (C) Frequencies of IFNγ secreting cells in
Foxp3−CD4+ and Foxp3+CD4+ T cells isolated from diseased Mirn146a−/−/Foxp3KO are
shown. miR-146a-deficient T effector subset appears to make somewhat less IFNγ as
compared to Foxp3ko T cell subset because the latter contains an increased frequency of self-
reactive T cells due to the presence of Treg “wannabe’s” (Hsieh et al., 2006). The
proportions (D) and absolute numbers (E) of IFNγ secreting cells in Foxp3+CD4+ Treg cells
isolated from diseased Mirn146a−/−/Foxp3KO chimeric mice are numerated. Data are
representative of three independent experiments (n=11-13); values represent the mean +/−
s.d., *P<0.05. (F) Frequency of IFNγ secreting cells in Foxp3−CD4+ and Foxp3+CD4+ T
cells isolated from healthy Mirn146a−/−/B6 mice are shown. Data are representative of three
independent experiments (n=11-13). See also Figure S3.
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Fig 3. IFNγ blockade rescued immune mediated pathology in mice harboring miR-146a-deficient
Treg cells
(A) Schematic of IFNγ neutralization experiments using BM chimeras. (B) Splenic Treg cell
frequencies in chimeric mice treated with IFNγ neutralizing or control antibodies 6 weeks
after BM transfer. (C) Expression of Ki67 and other activation markers in miR-146a-
sufficient Ly5.1+Foxp3−CD4+ Teff cells isolated from Mirn146a−/−/Foxp3KO mice with
IFNγ neutralizing or control antibodies. (D) Frequency of IFNγ, IL-4, and IL-17 secreting
cells in miR-146a-sufficient Ly5.1+Foxp3− CD4+ Teff cell subsers from indicated chimeric
mice with or without αIFNγ treatment are shown. Ly5.1+Foxp3− CD4+ Teff cells isolated
from chimeric mice reconstituted with Foxp3KO BM only served as positive control. Data
are representative of two independent experiments (n=9-12).
Lu et al. Page 20
Cell. Author manuscript; available in PMC 2011 March 17.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig 4. Loss of miR-146a-mediated Stat1 repression contributes to the IFNγ-mediated Th1
pathology in mice harboring miR-146a-deficient Treg cells
(A) Multiple species sequence alignment of the Stat1 3′ UTR including the putative
miR-146a target site sequence (bold). (B) CD4+ T cells isolated from miR-146a-deficient or
-sufficient mice were co-transfected with a luciferase reporter construct containing wild-type
or mutated Stat1 3′UTR and assessed for luciferase activity 24hrs after transfection. (C)
Immunoblot analysis of the Stat1, TRAF6 and IRAK1 protein expression as well as the
phosphrylation of Stat1. Densitometric values normalized on the basis of β-actin expression
are indicated below the corresponding lanes; fold increase in normalized target protein
expression in the absence of miR-146a with or without IFNγ neutralization in the indicated
T cell subsets. Data are representative of two independent experiments. (D) Immunoblot
analysis of total Stat1 as well as the phosphorylated Stat1 protein in mice with Stat1
hemizygosity. Densitometric values normalized on the basis of β-actin expression as well as
fold increase in normalized target protein expression in the indicated T cell subsets are
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shown below the corresponding lanes. (E) Kaplan-Meyer survival plot of Rag2−/− mice
reconstituted with 1:1 mixtures of indicated BM cells. Arrows indicate the time of analysis.
Frequency of (F) IFNγ or (G) IL-4 secreting cells in Foxp3−CD4+ and Foxp3+CD4+ T cell
subsets in diseased mirn146−/−Stat1+/+/Foxp3KO and mirn146−/−Stat1−/+/Foxp3KO
chimeric mice. Data are representative of two independent experiments (n=13).
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Fig 5. IFNγ production by miR-146a-deficient T cells partially contributed to, but cannot
account for Th1 immunopathology in Mirn146a−/−/Foxp3KO mice
(A) CD4+CD25−CD62Lhi cells isolated from Mirn146a−/− mice or wild-type littermates
were cultured in vitro under Th1/Th2 polarizing conditions. Intracellular IFNγ and IL-4
staining was assessed by FACS analysis. Data are representative of three independent
experiments (n=4-6). (B) Schematic of generation of mixed BM chimeras. Frequencies of
IFNγ secreting cells in (C) CD4+ and (D) CD8+ T cell population isolated from indicated
chimeric mice are shown. (E) Flow cytometric analysis of expression of activation markers
and Ki67 in miR-146a-sufficient Ly5.1+Foxp3−CD4+ Teff cells from indicated chimeric
mice are shown. Data are representative of three independent experiments (n=6-7). Real-
time PCR analysis of (F) primary miR-146a, (G) mature miR-146a as well as (H) T-bet and
(I) Foxp3 mRNA expression in FACS-purified CXCR3+ and CXCR3− populations from
CD4+CD25+ Treg cells (TR) and CD4+CD25−CD62Lhi R naïve T cells (TN). Data are
representative of two independent experiments.
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Fig 6. Phenotypic analysis of mice subjected Treg cell-specific SOCS1 ablation
Flow-cytometric analysis of (A) thymus and (B) spleen cells of 6-8 week-old
Foxp3creSOCS1fl/fl mice and wild-type littermates. Percentages of different thymocyte and
splenocyte subsets are shown. (C-F) Cellularity of the thymus and spleen and the
protportion and absolute numbers of thymus and splenic Foxp3+CD4+ Treg cells in
Foxp3creSOCS1fl/fl mice or wild-type littermates are shown. Data are representative of three
independent experiments (n=6-8); values represent the mean +/− s.d.; *P<0.05. (G) H&E-
stained sections of the skin, liver, and lung from the indicated chimeric mice. Flow-
cytometric analysis of expression of Ki67 and other activation markers in (H) Foxp3−CD4+
Teff cells and (I) Foxp3+CD4+ Treg cells in 6-8 week old Foxp3creSOCS1fl/fl mice (blue) or
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wild-type littermates (red). Data are representative of two independent experiments (n=6-8).
See also Figure S4.
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Fig 7. Unrestrained Stat1 activation in SOCS1-deficient Treg cells is associated with
dysregulated IFNγ responses
(A) SOCS1-deficient or -sufficient Treg cells were co-cultured with wild-type responder
CD4+ T cells at the indicated ratios for 72 h in the presence of CD3 antibody and irradiated
(2000 rads) T cell-depleted splenocytes. (B) Immunoblot analysis of total and phospho-
Stat1. Densitometric values normalized on the basis of β-actin expression and fold increase
in normalized target protein expression in the indicated T cell subsets are indicated below
the corresponding lanes. (C) Frequencies of IFNγ secreting cells within Foxp3−CD4+ and
Foxp3+CD4+ as well as CD8+ subsets in Foxp3creSOCS1fl/fl mice or wild-type littermates.
Data are representative of two independent experiments. See also Figure S5.
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